Impression Healthcare (ASX: IHL)


Impression Healthcare (ASX: IHL) is aimed at disrupting the way Australians access quality, affordable, custom-fit mouthguards for individuals, schools and sports clubs nationwide. www.impression.healthcare

Incannex Healthcare IHL ASX first patients phase 2 obstructive sleep apnoea clinical trial

Incannex Healthcare recruits for IHL-42X obstructive sleep apnoea clinical trial

On a path to developing a suite of cannabinoid-based medicines aimed at remedying a range of debilitating conditions, pharmaceutical development...
Incannex Healthcare ASX IHL IHL-216A traumatic brain injury in vivo cannabidiol TBI

Pre-clinical research of Incannex Healthcare’s IHL-216A drug found it effective preventing traumatic brain injury

Incannex Healthcare (ASX: IHL) has revealed more positive in vivo research for its IHL-216A drug, this time regarding traumatic brain injury and...
Incannex Healthcare ASX IHL Monash University psilocybin assisted psychotherapy anxiety disorder

Incannex Healthcare and Monash University to undertake ‘world first’ trial using psilocybin mushrooms to treat anxiety

Incannex Healthcare (ASX: IHL) has partnered with Monash University to undertake a “world first” clinical trial using psilocybin-assisted psycho...
Incannex Healthcare ASX IHL in vivo drug COVID-19 infection anti-inflammatory

Incannex Healthcare reveals positive in vivo results, will call Pre-IND meeting with FDA

Cannabinoid development company Incannex Healthcare (ASX: IHL) has unveiled the latest test results of its lead drug candidate IHL-675A, which s...
Incannex Healthcare trading halt study results FDA strategy ASX IHL

Incannex Healthcare enters trading halt ahead of study results and FDA strategy

Cannabinoid drug development company Incannex Healthcare (ASX: IHL) could be on the cusp of announcing a significant development in its mission ...
Incannex Healthcare ASX IHL hydroxychloroquine cannabidiol inhibit inflammation SAARDS

Incannex lead drug candidate exhibits stronger anti-inflammatory action than CBD in preclinical studies

Clinical-stage cannabinoid development company Incannex Healthcare (ASX: IHL) has received positive results from pre-clinical in vitro studies i...
Incannex ASX IHL medicinal cannabis oil pharmaceutical company Australia Special Access Scheme

Incannex achieves record medicinal cannabis oil sales as pure play pharmaceutical company

Incannex (ASX: IHL) has reported its highest quarterly sales for the September period – beating its previous June quarter record. For the thr...
Incannex Healthcare IHL ASX cannabinoid Obstructive Sleep Apnoea clinical trial

Incannex receives ethics approval for novel cannabinoid in phase 2b obstructive sleep apnoea trial

Incannex Healthcare (ASX: IHL) has received ethics approval for a phase 2b clinical trial to study the therapeutic benefits of its lead drug IHL...
Incannex Healthcare ASX IHL in vitro results sepsis-associated acute respiratory disease drug studies

Incannex announces in vitro results from sepsis-associated acute respiratory disease drug studies

Clinical-stage cannabinoid development company Incannex Healthcare (ASX: IHL) has announced positive preliminary results on the anti-inflammator...
Incannex ASX IHL animal trial establish optimal dosage treating traumatic brain injuries

Incannex commences animal trial to establish optimal dosage of IHL-216A in treating traumatic brain injuries

Cannabinoid development company Incannex Healthcare (ASX: IHL) has commenced a pre-clinical animal trial investigating the neuroprotective capab...
Incannex Healthcare ASX IHL COVID-19 sepsis-associated acute respiratory distress syndrome SAARDS study cannabis

Incannex reports positive results from animal study into CBD-based drug for ARDS resulting from COVID-19

After reporting amiable progress concerning its sleep apnoea drug IHL-42X just last week, cannabinoid drug development company Incannex Healthca...
Incannex Healthcare ASX IHL The Alfred Hospital CBD drug patients obstructive sleep apnoea

Incannex partners with The Alfred Hospital for clinical trial to study impact of cannabinoid drug on patients with obstr...

Clinical stage cannabinoid development company Incannex Healthcare (ASX: IHL) has partnered with The Alfred Hospital in Melbourne for a phase 2b...
Incannex Healthcare ASX IHL record sales cannabis oil CBD Cannagesia

Incannex Healthcare shifts from making an impression to setting sales records

Cannabinoid development company Incannex Healthcare (ASX: IHL) has published provisional performance figures for the past quarter, declaring a “...
Impression Healthcare ASX IHL oral devises cannabinoid product sales COVID-19

Impression Healthcare to focus exclusively on cannabinoid sales and drug development

Medical cannabis company Impression Healthcare (ASX: IHL) has announced it will discontinue sales of its oral devices by the end of the month to...
Impression Healthcare CBD drug trial leading cause of COVID-19 deaths ASX IHL acute respiratory distress syndrome

Impression Healthcare starts CBD drug trial to fight leading cause of COVID-19 deaths

Impression Healthcare (ASX: IHL) has begun the first clinical trial to assess the effectiveness of its cannabidiol (CBD) based drug IHL-675A aga...
Impression Healthcare ASX IHL rugby league footballer James Graham

Impression Healthcare recruits NRL star James Graham to boost commercial development of IHL-216A

Medical cannabis company Impression Healthcare (ASX: IHL) has unveiled a high profile acquisition in the form of professional rugby league footb...
Impression Healthcare animal testing CBD drug COVID-19 related respiratory conditions ASX IHL

Impression Healthcare to commence animal testing of CBD drug for COVID-19 related respiratory conditions

Impression Healthcare (ASX: IHL) has confirmed in it quarterly report that it has sourced all permits and products required for the start of ani...
Impression Healthcare ASX IHL 2024 commercialisation cannabinoid treatment traumatic brain injury

Impression Healthcare targets 2024 commercialisation of cannabinoid treatment for traumatic brain injury

Medical cannabis company Impression Healthcare (ASX: IHL) has confirmed plans to bring its novel cannabinoid formula IHL-216A for patients with ...
Impression Healthcare Hydroxychloroquine CBD cannabis COVID-19 coronavirus induced ARDS Adult Respiratory Distress Syndrome

Impression Healthcare develops CBD-based drug as potential treatment for coronavirus symptoms

Medicinal cannabis company Impression Healthcare (ASX: IHL) has developed a cannabidiol (CBD) based drug that it believes holds potential for th...
Impression Healthcare FDA cannabinoid drug candidate IHL-42X Camargo Pharmaceuticals ASX IHL

Impression Healthcare sets out FDA approval strategy for cannabinoid drug candidate IHL-42X

Medical cannabis company Impression Healthcare (ASX: IHL) has revealed it has received an independent strategic assessment report on the FDA app...
Impression Healthcare CBD inhalers Australia Special Access Scheme lung inflammation COVID-19 coronavirus Asthma COPD Ventilin

Impression Healthcare acquires CBD inhalers for distribution under Australia’s Special Access Scheme

Medical cannabis company Impression Healthcare (ASX: IHL) came out of a trading halt late this morning to unveil an initial order for cannabidio...